Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
NCT03471260Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib, venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2018; status: recruiting.
02
Drugs
ivosidenibvenetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT03471260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471260.